Cargando…

MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines

MicroRNAs (miRNAs) regulate gene expression post-transcriptionally. In this way they might influence whether a cell is sensitive or resistant to a certain drug. So far, only a limited number of relatively small scale studies comprising few cell lines and/or drugs have been performed. To obtain a bro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uhr, Katharina, Prager-van der Smissen, Wendy J. C., Heine, Anouk A. J., Ozturk, Bahar, van Jaarsveld, Marijn T. M., Boersma, Antonius W. M., Jager, Agnes, Wiemer, Erik A. C., Smid, Marcel, Foekens, John A., Martens, John W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504094/ https://www.ncbi.nlm.nih.gov/pubmed/31063487 http://dx.doi.org/10.1371/journal.pone.0216400

Ejemplares similares

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs
por: Riaz, Muhammad, et al.
Publicado: (2013)

Understanding drugs in breast cancer through drug sensitivity screening
por: Uhr, Katharina, et al.
Publicado: (2015)

Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer
por: Bastiaansen, Anna E. M., et al.
Publicado: (2020)

Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1(st)-line tamoxifen therapy in breast cancer
por: Uhr, K., et al.
Publicado: (2018)

Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers
por: Weerts, Marjolein J. A., et al.
Publicado: (2018)

Tissue-Specific Chk1 Activation Determines Apoptosis by Regulating the Balance of p53 and p21
por: van Jaarsveld, Marijn T.M., et al.
Publicado: (2019)

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway
por: van Jaarsveld, Marijn T. M., et al.
Publicado: (2015)

Co-regulated gene expression of splicing factors as drivers of cancer progression
por: Koedoot, Esmee, et al.
Publicado: (2019)

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
por: van den Ende, Nadine S., et al.
Publicado: (2022)

Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk
por: Liu, Jingjing, et al.
Publicado: (2016)

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
por: Verschoor, Noortje, et al.
Publicado: (2023)

An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer
por: van der Noord, Vera E., et al.
Publicado: (2019)

Cell-type-specific role of CHK2 in mediating DNA damage-induced G2 cell cycle arrest
por: van Jaarsveld, Marijn T. M., et al.
Publicado: (2020)

Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis
por: Weerts, Marjolein J.A., et al.
Publicado: (2016)

A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds
por: Mustafa, Dana A. M., et al.
Publicado: (2015)

High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes
por: Riaz, Muhammad, et al.
Publicado: (2012)

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy
por: McLaughlin, Ronan P., et al.
Publicado: (2019)

Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile
por: Smid, Marcel, et al.
Publicado: (2023)

Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes
por: Koedoot, Esmee, et al.
Publicado: (2019)

Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression
por: He, Jichao, et al.
Publicado: (2020)

Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
por: Yu, Jack X, et al.
Publicado: (2007)

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome
por: de Kruijff, Ingeborg E., et al.
Publicado: (2018)

Circular RNA in Chemonaive Lymph Node Negative Colon Cancer Patients
por: van den Berg, Inge, et al.
Publicado: (2021)

Proteomic characterization of microdissected breast tissue environment provides a protein‐level overview of malignant transformation
por: Braakman, René B. H., et al.
Publicado: (2017)

A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity
por: Deger, Teoman, et al.
Publicado: (2022)

An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients
por: Reijm, Esther A., et al.
Publicado: (2016)

Global proteomic characterization of microdissected estrogen receptor positive breast tumors
por: De Marchi, Tommaso, et al.
Publicado: (2015)

Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients
por: de Kruijff, I. E., et al.
Publicado: (2021)

Lost by Transcription: Fork Failures, Elevated Expression, and Clinical Consequences Related to Deletions in Metastatic Colorectal Cancer
por: Smid, Marcel, et al.
Publicado: (2022)

Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients
por: Liu, Ning Qing, et al.
Publicado: (2016)

MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells
por: Nyhan, Michelle J., et al.
Publicado: (2016)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor()
por: Beije, Nick, et al.
Publicado: (2016)

DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells
por: Ansems, Marleen, et al.
Publicado: (2015)

Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2017)

Identifying Transcripts with Tandem Duplications from RNA-Sequencing Data to Predict BRCA1-Type Primary Breast Cancer
por: Qu, Shuoying, et al.
Publicado: (2022)

Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like–Induced Protein Changes in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Throughout Disease Progression
por: Bos, Manouk K., et al.
Publicado: (2022)

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival
por: Verschoor, Noortje, et al.
Publicado: (2023)

T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression
por: Mustafa, Dana A. M., et al.
Publicado: (2018)

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015)

MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation
por: Zubakov, Dmitry, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_p5dd0942teovj4b5iopiqi3scs